Triple Negative Breast Cancer
Showing NaN - NaN of 13
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative Trial in United States (Atezolizumab, Carboplatin,
Active, not recruiting
- Triple Negative Breast Cancer
- +3 more
- Atezolizumab
- +3 more
-
Washington, District of Columbia
- +5 more
Dec 1, 2022
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)
Completed
- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
-
Birmingham, Alabama
- +24 more
Sep 19, 2022
NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +5 more
- CART-TnMUC1
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 18, 2022
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer Trial in United States (Atezolizumab, Sacituzumab govitecan)
Recruiting
- Breast Cancer
- +3 more
- Atezolizumab
- Sacituzumab govitecan
-
San Francisco, California
- +8 more
May 25, 2022
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +
Recruiting
- Advanced Solid Tumor
- +8 more
- PY314
- Combination Therapy: PY314 + Pembrolizumab
-
Scottsdale, Arizona
- +12 more
Mar 28, 2022
Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma Trial in United States (AVID100 IV)
Terminated
- Solid Tumor, Adult
- +3 more
- AVID100 IV
-
New Haven, Connecticut
- +9 more
Mar 22, 2021
Metastatic Breast Cancer, Triple Negative Breast Cancer Trial in Philadelphia (cMet RNA CAR T cells)
Completed
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- cMet RNA CAR T cells
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Oct 17, 2018
Triple Negative Breast Cancer Trial in Stanford, Philadelphia (gemcitabine plus carboplatin plus BSI-201)
Completed
- Triple Negative Breast Cancer
- gemcitabine plus carboplatin plus BSI-201
-
Stanford, California
- +1 more
Feb 17, 2016